Bolt Biotherapeutics (BOLT) Capital Expenditures (2020 - 2025)
Bolt Biotherapeutics (BOLT) posted Capital Expenditures of $72000.0 for Q3 2025, up 1700.0% sequentially from $4000.0 in Q3 2024, and up 1700.0% YoY from $4000.0 in Q3 2024.
Bolt Biotherapeutics (BOLT) Capital Expenditures (2020 - 2025) Analysis & Trends
Bolt Biotherapeutics has reported Capital Expenditures for 6 years, with the latest figure at $72000.0 in Q3 2025.
- Quarterly Capital Expenditures rose 1700.0% year-over-year to $72000.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $76000.0 (up 85.37% YoY) and the FY2025 annual result came in at $72000.0, up 75.61% from the prior year.
- Capital Expenditures grew to $72000.0 in Q3 2025 per BOLT's latest filing, from $4000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $1.0 million in Q3 2021 and troughed at -$755000.0 in Q4 2021.
- A 5-year average of $215933.3 and a median of $72000.0 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2021 and 2025: Capital Expenditures tumbled 131.42% in 2021, then surged 1700.0% in 2025.
- Over 5 years, Capital Expenditures stood at -$755000.0 in 2021, then jumped by 124.37% to $184000.0 in 2022, then slumped by 126.09% to -$48000.0 in 2023, then jumped by 108.33% to $4000.0 in 2024, then soared by 1700.0% to $72000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $72000.0, $4000.0, and $37000.0 for Q3 2025, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Bolt Biotherapeutics | 6.10 Mn | 6.10 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 72,000.00 |
| Sep 30, 2025 | 72,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 37,000.00 |
| Jun 30, 2024 | 37,000.00 |
| Dec 31, 2023 | -48,000.00 |
| Dec 31, 2023 | -48,000.00 |
| Sep 30, 2023 | 165,000.00 |
| Sep 30, 2023 | 165,000.00 |
| Jun 30, 2023 | -11,000.00 |
| Jun 30, 2023 | -11,000.00 |
| Mar 31, 2023 | 46,000.00 |
| Mar 31, 2023 | 46,000.00 |
| Dec 31, 2022 | 184,000.00 |
| Dec 31, 2022 | 184,000.00 |
| Sep 30, 2022 | 735,000.00 |
| Sep 30, 2022 | 735,000.00 |
| Jun 30, 2022 | 429,000.00 |
| Jun 30, 2022 | 429,000.00 |